Thursday, March 25, 2021 12:55:52 AM
I was very pleased to hear that Sorrento now owns 100% of Scilex. It will be a real cash cow with SP-102 and RTX approvals and ARD-301 for long haulers could be big.
And Abivertinib , ADNAB, plasmid DNA and Dar-T in dozens of cancer applications have oustanding potential. These are all first-in-class and best-in-class IMO.
But I must admit I am amazed by the Celularity and ImmunityBio investment potential. And if there's any justice in this world PSS will soon be handing over $1+ billions to Sorrento. I've never before invested in such a well funded...wide portfolio...small biotech!
"The refusal of the real is the number one dogma of our time" Rene Girard
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM